MaxVal’s new semiweekly column provides insights into recently issued patents and applications for some of the most innovative companies in the world.
In this post, we take you through some of the recent patents and applications from Intel, Apple, Google, Amazon, Facebook, Merck, Medtronic, Novartis, Pfizer, and Roche.
Apple files patent on adjustable stylus and a watch that detects false rotations
US Patent 10,222,909 entitled “Rejection of False Turns of Rotary Inputs for Electronic Devices” seeks to improve user experience by using optical detection to differentiate between valid and invalid turns of a user and rejects unintended rotations by measuring the distance between the device and the wearer’s forearm or hand. Figures illustrate a wearable electronic device having rotary inputs and user’s arm which can generate false turns of a rotary input.
US Patent Publication 20190064936 entitled “Adjustable Handheld Stylus” relates to a stylus with adjustable element to mimic characteristics of a writing/drawing tool or to fit into the user’s hand precisely. Figures illustrate cross-sectional view of an exemplary stylus in different states.
Facebook’s filings on social media networks, augmented messaging, abuse detection, content delivery networks, and head mounted displays
One particular patent relating to head mounted displays “caught our eye” this week. US patent 10,222,622 entitled “Head Mounted Displays with Shaped Lenses“ claims a head mounted display assembly arrangement with a pair of circular lenses associated with a flat display panel. The invention provides a fix to a problem in the prior art regarding impacts to a user’s special perception, particularly in the peripheral regions of the user’s view.
Amazon wins patents for content delivery based on machine learning, voice controlled devices, and illuminated sign designs
Amazon’s recent US patent, 10,225,365, entitled “Machine Learning Based Content Delivery” discusses methods for managing content delivery functionalities based on machine learning by routing content requests and delivering content strategies based on a model trained on historical data. The figure below shows a block diagram of a content delivery environment including client computing devices, a content provider and a service provider.
Intel awarded patents in the area of wireless communications
The US patent 10,225,851, entitled “Multi-Cast Long Range Low Power Access Point“ adds to their wireless patent assets with an eye on Internet of Things (IoT) devices. It describes a system and techniques for a multi-class Long Range Lower Power (LRLP) access point with multi-factor intelligent agent control.
Another US patent 10,225,870, entitled “Device Setup States for Link Aggregation in Wireless Communications” describes systems, methods, and devices related to link aggregation between devices by determining frequency bands for sending data in the multi-band link aggregation session.
Google patents systems for video conferencing, video coding, interactive multi-screen experience and display screen and panel designs
One of Google’s recent assets 10,225,519 entitled “Using an Avatar in a Videoconferencing System” is about the use of an avatar during video conferencing. The avatar may be provided to a remote device to represent the user. Figure illustrates an electronic display in a videoconferencing system showing multiple windows.
Another US patent 10,223,060 entitled “Interactive Video Multi-Screen Experience on Mobile Phones” discusses interactive multi-screen experience on multiple mobile phones to collectively present a big screen experience on a combined display split across multiple mobile devices. Figure shows an example of the panning of a set of video content items.
Google won a patent 10,216,335 for reducing false sensing of touchscreen input by using dummy electrodes that extend from a touch controller to locations where contacts should not be detected. If a dummy electrode detects a contact, then no contact will be detected and/or recognized by the touchscreen. Figure is a flowchart representing an example method that may be used to reduce false sensing of touchscreen inputs.
Medtronic receives patents for clot assessment, communication systems, neurostimulation, RF ablation, and cardiac valves
Medtronic’s recent application 20190066831 on “Medical Devices and Related Event Pattern Presentation Methods” discusses a patient management system including an infusion system and a computing device. The system identifies event patterns within a plurality of monitoring periods, prioritizes the event patterns, filters the prioritized list and provides a respective pattern guidance display for each respective event pattern on a display device. The figure depicts an exemplary embodiment of an infusion system.
Merck’s new molecules, materials, and genetic tests for predicting treatment success
US patent 10,221,456, entitled “Genetic Markers for Predicting Responsiveness to FPF-18 Compound” deals with use of biomarkers in predicting supersensitivity to treatment with an FGF-18 compound of a patient having a cartilage disorder, such as osteoarthritis, cartilage injury, by determining the genotype at both loci IL-1RN rs9005 and IL-1RN rs315952.
Another US patent 10,219,989 entitled “Special Effects with Mixtures of Interference Pigments” was granted for a method of producing mixtures of interference pigments having special effects which are compatible with a various color systems, preferably used in cosmetics and personal care products, paints, coatings and printing inks.
One of 5 recent published applications 20190067576 relates to a novel method for preparing spirobifluorene derivatives of high purity with more yield and reduced fabrication costs. The spirobifluorene derivatives are suitable for use in a fluorescent or phosphorescent OLED as a raw material in a hole-transport or exciton-blocking layer or as matrix material in an emitting layer.
Novartis continues its war on cancer
Chimeric antigen receptor (CAR) modified autologous T cell (CART) therapy has emerged as a leading candidate in the fight against certain cancers. The patent, US 10,221,245 entitled, “Treatment of Cancer Using Humanized Anti-CD19 Chimeric Antigen Receptor“ is directed to a specific humanized CAR19 scFv.
Pfizer wins patent for EGFRvII targeted antibody
EGFR signalling aberration in tumors is frequently targeted for treatment. EGFR variant III (EGFRvIII) is one such tumor specific mutant of EGFR which loses its ability to bind ligands but acquires constitutive kinase activity. Pfizer’s US patent 10,221,242 relates to mono-specific antibodies targeting EGFRvIII and bispecific antibodies targeting CD3 and EGFRvIII, compositions, conjugates, vectors, cells, and method of use thereof.
Did you like this piece of content? We would love to hear your thoughts! Leave a reply below to let us know which companies you would like to see us follow, and any other suggestions you might have. Be sure to subscribe to our blog to stay up to date with the latest information on patents, applications, and more.